March 18, 2026  - illumiSonics Inc., a leading innovator in advanced biomedical imaging technologies, is pleased to announce the appointment of James Tweel as Principal Research Scientist. Dr. Tweel brings extensive expertise in biomedical imaging and has played a critical role in the development of the company’s core technologies, PARS® (Photon Absorption Remote Sensing) and MLI® (Multi-Laser Imaging), which serve as central pillars of illumiSonics’ proprietary imaging platf

Unenhanced MLI® of an unstained pelvic biopsy specimen readily identifies areas of endometriosis.

Unenhanced whole slide MLI® of human skin cancer demonstrating basal cell carcinoma (BCC) architecture. Tissue and interpretation from Dr. Marie Abi Daoud, University of Calgary. 

Unenhanced MLI® alongside MLI® virtual H&E showing the diagnostic features of human breast ductal carcinoma in situ. Tissue courtesy of Ontario Institute for Cancer Research. 

MLI® virtual HER2 staining performance compared against ground truth HER2 Immunohistochemical staining. MLI® virtual HER2 staining shows strong concordance and localization across the distribution of HER2 seen in clinical samples.